Selected research
Industry Research
Histone Deacetylase 2 Industry Research Report 2026
Market perspective
The global Histone Deacetylase 2 market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Histone Deacetylase 2 is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Histone Deacetylase 2 is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Histone Deacetylase 2 is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Histone Deacetylase 2 include 4SC AG, Merck & Co., Inc., GlaxoSmithKline Plc, Yungjin Pharm. Co., Ltd., TetraLogic Pharmaceuticals, Sigma-Tau S.p.A., Rodin Therapeutics, MEI Pharma, Inc. and Italfarmaco S.p.A., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Histone Deacetylase 2 market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Histone Deacetylase 2 Market by Company
4SC AG
Merck & Co., Inc.
GlaxoSmithKline Plc
Yungjin Pharm. Co., Ltd.
TetraLogic Pharmaceuticals
Sigma-Tau S.p.A.
Rodin Therapeutics
MEI Pharma, Inc.
Italfarmaco S.p.A.
HitGen LTD
Curis, Inc.
Chipscreen Biosciences Ltd
Acetylon Pharmaceuticals, Inc.
Histone Deacetylase 2 Segment by Type
ACY-957
CS-3158
HG-3001
RCY-1305
Others
Histone Deacetylase 2 Segment by Application
Bladder Cancer
Non-Hodgkin Lymphoma
Colon Cancer
Alopecia
Others
Histone Deacetylase 2 Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Histone Deacetylase 2 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Histone Deacetylase 2 and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Histone Deacetylase 2.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Histone Deacetylase 2 manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Histone Deacetylase 2 by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Histone Deacetylase 2 in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- ACY-957
- CS-3158
- HG-3001
- RCY-1305
- Others
Applications
- Bladder Cancer
- Non-Hodgkin Lymphoma
- Colon Cancer
- Alopecia
- Others
Companies covered
- 4SC AG
- Merck & Co., Inc.
- GlaxoSmithKline Plc
- Yungjin Pharm. Co., Ltd.
- TetraLogic Pharmaceuticals
- Sigma-Tau S.p.A.
- Rodin Therapeutics
- MEI Pharma, Inc.
- Italfarmaco S.p.A.
- HitGen LTD
- Curis, Inc.
- Chipscreen Biosciences Ltd
- Acetylon Pharmaceuticals, Inc.
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Histone Deacetylase 2 Market Size (2021-2032)
- 2.2.2 Global Histone Deacetylase 2 Sales (2021-2032)
- 2.2.3 Global Histone Deacetylase 2 Market Average Price (2021-2032)
- 2.3 Histone Deacetylase 2 by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 ACY-957
- 2.3.3 CS-3158
- 2.3.4 HG-3001
- 2.3.5 RCY-1305
- 2.3.6 Others
- 2.4 Histone Deacetylase 2 by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Bladder Cancer
- 2.4.3 Non-Hodgkin Lymphoma
- 2.4.4 Colon Cancer
- 2.4.5 Alopecia
- 2.4.6 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Histone Deacetylase 2 Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Histone Deacetylase 2 Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Histone Deacetylase 2 Revenue of Manufacturers (2021-2026)
- 3.4 Global Histone Deacetylase 2 Average Price by Manufacturers (2021-2026)
- 3.5 Global Histone Deacetylase 2 Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Histone Deacetylase 2, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Histone Deacetylase 2, Product Type & Application
- 3.8 Global Manufacturers of Histone Deacetylase 2, Established Date
- 3.9 Global Histone Deacetylase 2 Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 4SC AG
- 4.1.1 4SC AG Company Information
- 4.1.2 4SC AG Business Overview
- 4.1.3 4SC AG Histone Deacetylase 2 Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 4SC AG Histone Deacetylase 2 Product Portfolio
- 4.1.5 4SC AG Recent Developments
- 4.2 Merck & Co., Inc.
- 4.2.1 Merck & Co., Inc. Company Information
- 4.2.2 Merck & Co., Inc. Business Overview
- 4.2.3 Merck & Co., Inc. Histone Deacetylase 2 Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Merck & Co., Inc. Histone Deacetylase 2 Product Portfolio
- 4.2.5 Merck & Co., Inc. Recent Developments
- 4.3 GlaxoSmithKline Plc
- 4.3.1 GlaxoSmithKline Plc Company Information
- 4.3.2 GlaxoSmithKline Plc Business Overview
- 4.3.3 GlaxoSmithKline Plc Histone Deacetylase 2 Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 GlaxoSmithKline Plc Histone Deacetylase 2 Product Portfolio
- 4.3.5 GlaxoSmithKline Plc Recent Developments
- 4.4 Yungjin Pharm. Co., Ltd.
- 4.4.1 Yungjin Pharm. Co., Ltd. Company Information
- 4.4.2 Yungjin Pharm. Co., Ltd. Business Overview
- 4.4.3 Yungjin Pharm. Co., Ltd. Histone Deacetylase 2 Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Yungjin Pharm. Co., Ltd. Histone Deacetylase 2 Product Portfolio
- 4.4.5 Yungjin Pharm. Co., Ltd. Recent Developments
- 4.5 TetraLogic Pharmaceuticals
- 4.5.1 TetraLogic Pharmaceuticals Company Information
- 4.5.2 TetraLogic Pharmaceuticals Business Overview
- 4.5.3 TetraLogic Pharmaceuticals Histone Deacetylase 2 Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 TetraLogic Pharmaceuticals Histone Deacetylase 2 Product Portfolio
- 4.5.5 TetraLogic Pharmaceuticals Recent Developments
- 4.6 Sigma-Tau S.p.A.
- 4.6.1 Sigma-Tau S.p.A. Company Information
- 4.6.2 Sigma-Tau S.p.A. Business Overview
- 4.6.3 Sigma-Tau S.p.A. Histone Deacetylase 2 Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Sigma-Tau S.p.A. Histone Deacetylase 2 Product Portfolio
- 4.6.5 Sigma-Tau S.p.A. Recent Developments
- 4.7 Rodin Therapeutics
- 4.7.1 Rodin Therapeutics Company Information
- 4.7.2 Rodin Therapeutics Business Overview
- 4.7.3 Rodin Therapeutics Histone Deacetylase 2 Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Rodin Therapeutics Histone Deacetylase 2 Product Portfolio
- 4.7.5 Rodin Therapeutics Recent Developments
- 4.8 MEI Pharma, Inc.
- 4.8.1 MEI Pharma, Inc. Company Information
- 4.8.2 MEI Pharma, Inc. Business Overview
- 4.8.3 MEI Pharma, Inc. Histone Deacetylase 2 Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 MEI Pharma, Inc. Histone Deacetylase 2 Product Portfolio
- 4.8.5 MEI Pharma, Inc. Recent Developments
- 4.9 Italfarmaco S.p.A.
- 4.9.1 Italfarmaco S.p.A. Company Information
- 4.9.2 Italfarmaco S.p.A. Business Overview
- 4.9.3 Italfarmaco S.p.A. Histone Deacetylase 2 Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Italfarmaco S.p.A. Histone Deacetylase 2 Product Portfolio
- 4.9.5 Italfarmaco S.p.A. Recent Developments
- 4.10 HitGen LTD
- 4.10.1 HitGen LTD Company Information
- 4.10.2 HitGen LTD Business Overview
- 4.10.3 HitGen LTD Histone Deacetylase 2 Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 HitGen LTD Histone Deacetylase 2 Product Portfolio
- 4.10.5 HitGen LTD Recent Developments
- 4.11 Curis, Inc.
- 4.11.1 Curis, Inc. Company Information
- 4.11.2 Curis, Inc. Business Overview
- 4.11.3 Curis, Inc. Histone Deacetylase 2 Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Curis, Inc. Histone Deacetylase 2 Product Portfolio
- 4.11.5 Curis, Inc. Recent Developments
- 4.12 Chipscreen Biosciences Ltd
- 4.12.1 Chipscreen Biosciences Ltd Company Information
- 4.12.2 Chipscreen Biosciences Ltd Business Overview
- 4.12.3 Chipscreen Biosciences Ltd Histone Deacetylase 2 Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Chipscreen Biosciences Ltd Histone Deacetylase 2 Product Portfolio
- 4.12.5 Chipscreen Biosciences Ltd Recent Developments
- 4.13 Acetylon Pharmaceuticals, Inc.
- 4.13.1 Acetylon Pharmaceuticals, Inc. Company Information
- 4.13.2 Acetylon Pharmaceuticals, Inc. Business Overview
- 4.13.3 Acetylon Pharmaceuticals, Inc. Histone Deacetylase 2 Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Acetylon Pharmaceuticals, Inc. Histone Deacetylase 2 Product Portfolio
- 4.13.5 Acetylon Pharmaceuticals, Inc. Recent Developments
5 Global Histone Deacetylase 2 Market Scenario by Region
- 5.1 Global Histone Deacetylase 2 Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Histone Deacetylase 2 Sales by Region: 2021-2032
- 5.2.1 Global Histone Deacetylase 2 Sales by Region: 2021-2026
- 5.2.2 Global Histone Deacetylase 2 Sales by Region: 2027-2032
- 5.3 Global Histone Deacetylase 2 Revenue by Region: 2021-2032
- 5.3.1 Global Histone Deacetylase 2 Revenue by Region: 2021-2026
- 5.3.2 Global Histone Deacetylase 2 Revenue by Region: 2027-2032
- 5.4 North America Histone Deacetylase 2 Market Facts & Figures by Country
- 5.4.1 North America Histone Deacetylase 2 Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Histone Deacetylase 2 Sales by Country (2021-2032)
- 5.4.3 North America Histone Deacetylase 2 Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Histone Deacetylase 2 Market Facts & Figures by Country
- 5.5.1 Europe Histone Deacetylase 2 Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Histone Deacetylase 2 Sales by Country (2021-2032)
- 5.5.3 Europe Histone Deacetylase 2 Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Histone Deacetylase 2 Market Facts & Figures by Country
- 5.6.1 Asia Pacific Histone Deacetylase 2 Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Histone Deacetylase 2 Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Histone Deacetylase 2 Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Histone Deacetylase 2 Market Facts & Figures by Country
- 5.7.1 South America Histone Deacetylase 2 Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Histone Deacetylase 2 Sales by Country (2021-2032)
- 5.7.3 South America Histone Deacetylase 2 Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.7.7 Colombia
- 5.8 Middle East and Africa Histone Deacetylase 2 Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Histone Deacetylase 2 Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Histone Deacetylase 2 Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Histone Deacetylase 2 Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Histone Deacetylase 2 Sales by Type (2021-2032)
- 6.1.1 Global Histone Deacetylase 2 Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Histone Deacetylase 2 Sales Market Share by Type (2021-2032)
- 6.2 Global Histone Deacetylase 2 Revenue by Type (2021-2032)
- 6.2.1 Global Histone Deacetylase 2 Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Histone Deacetylase 2 Revenue Market Share by Type (2021-2032)
- 6.3 Global Histone Deacetylase 2 Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Histone Deacetylase 2 Sales by Application (2021-2032)
- 7.1.1 Global Histone Deacetylase 2 Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Histone Deacetylase 2 Sales Market Share by Application (2021-2032)
- 7.2 Global Histone Deacetylase 2 Revenue by Application (2021-2032)
- 7.2.1 Global Histone Deacetylase 2 Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Histone Deacetylase 2 Revenue Market Share by Application (2021-2032)
- 7.3 Global Histone Deacetylase 2 Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Histone Deacetylase 2 Value Chain Analysis
- 8.1.1 Histone Deacetylase 2 Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Histone Deacetylase 2 Production Mode & Process
- 8.2 Histone Deacetylase 2 Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Histone Deacetylase 2 Distributors
- 8.2.3 Histone Deacetylase 2 Customers
9 Global Histone Deacetylase 2 Analyzing Market Dynamics
- 9.1 Histone Deacetylase 2 Industry Trends
- 9.2 Histone Deacetylase 2 Industry Drivers
- 9.3 Histone Deacetylase 2 Industry Opportunities and Challenges
- 9.4 Histone Deacetylase 2 Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst